COMMUNIQUÉS West-GlobeNewswire

Conavi Medical Reports Fiscal Second Quarter 2026 Results and Operational Highlights
28/05/2026
- Achieves U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System - Wins Multiple Industry Awards Recognizing Innovation and Leadership in Intravascular Imaging - Advances U.S. Commercial Readiness [...]
Aveanna Healthcare Announces Successful Debt Repricing
28/05/2026
ATLANTA, May 28, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH), a leading, diversified home care platform focusing on providing care to medically complex, high-cost patient [...]
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
28/05/2026
Submission Anticipated in Q4 2026 SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and [...]
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
28/05/2026
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV [...]
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
28/05/2026
SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced [...]
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
28/05/2026
XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026 SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today [...]
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
28/05/2026
Freising, Germany, May 28, 2026 (GLOBE NEWSWIRE) -- XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 [...]
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
28/05/2026
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation [...]
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
28/05/2026
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumours US trial (OCTOPOD-IP) is exploring [...]
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
28/05/2026
Repairon Announces Publication of Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon [...]
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28/05/2026
Orphan Drug Designation confers regulatory, financial and strategic advantages EO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patients EO2463 has shown complementary [...]
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
28/05/2026
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates [...]
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
28/05/2026
IQIRVO ® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1 [...]
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
28/05/2026
Les données concernant IQIRVO ® viennent enrichir les connaissances scientifiques sur la fatigue, en montrant des améliorations cliniquement significatives chez des patients présentant une fatigue modérée à sévère à l’ [...]
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
28/05/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
28/05/2026
Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs) Support Closing of Business [...]

Pages